Barclays Reiterates Overweight Rating on C4 Therapeutics (CCCC)

Barclays analyst Etzer Darout reiterated an Overweight rating and $8.00 price target on C4 Therapeutics (NASDAQ: CCCC).

The analyst comments "We initiate coverage of C4 Therapeutics (CCCC) with an Overweight rating and $8 price target. C4 Therapeutics is a biopharmaceutical company focused on the development of small molecule protein degrader therapeutics for the treatment of various cancers. The company's lead asset, cemsidomide (CFT7455), is an IKZF1/3 degrader being developed in patients with multiple myeloma (MM) and selected non-Hodgkin lymphomas (NHL). Early phase 1 dose escalation data for cemsidomide has been encouraging and the company has recently shifted its development focus to the program. CCCC will present updated cemsidomide MM data September 17-20, as well as dose escalation data in NHL in 4Q. In its 2Q25 press release, CCCC noted a productive Type C meeting with the FDA and its registration development of cemsidomide in multiple myeloma is on track to initiate in early 2026. We view cemsidomide as potentially best-in-class IKZF1/3 degrader in a category where Revlimid (a first-generation IKZF1/3 degrader) delivered peak sales of $12.9 billion (2021). We believe CCCC is significantly undervalued despite encouraging data to date in the mega-bluster multiple myeloma market."

For an analyst ratings summary and ratings history on C4 Therapeutics click here. For more ratings news on C4 Therapeutics click here.

Shares of C4 Therapeutics closed at $3.57 yesterday.

You May Also Be Interested In

• Google Poised To Lose Two More Ai Staffers To Anthropic - Bloomberg
• Active options: INTC META ASST RUN NFLX AVGO HOOD ORCL IREN
• Plaintiff Drops All Claims Against GVA-Affiliated Defendant in Apple Creek Litigation